[ad_1] TORONTO, Jan. 8, 2025 /PRNewswire/ — AmacaThera, a leading clinical-stage biotechnology company revolutionizing long-acting therapies, announces the appointment of Dr. Eyal S. Ron to its Board of Directors. A seasoned entrepreneur and life sciences […]
[ad_1] VANCOUVER, BC, Jan. 6, 2025 /PRNewswire/ — Zero Candida Technologies, Inc. (TSXV: ZCT), (FSE: 9L2) (the “Company” or “ZCT”), an Israeli FemTech medical device company focused on revolutionizing women’s health, announces plans to complete preclinical studies […]
[ad_1] CRENESSITY, the first new treatment available in 70 years to the classic congenital adrenal hyperplasia (CAH) community, offers a paradigm-shifting treatment approach FDA approval supported by data from the largest-ever clinical trial program in […]
[ad_1] SILVER SPRING, Md., Dec. 13, 2024 /PRNewswire/ — Today, the U.S. Food and Drug Administration approved Crenessity (crinecerfont) to be used together with glucocorticoids (steroids) to control androgen (a testosterone-like hormone) levels in adults and […]
[ad_1] // NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES // VANCOUVER, BC, Dec. 13, 2024 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (“BioVaxys” or the […]
